Study design & results
Available in the Gosset platform where reported.
Trial intelligence / Profile preview
Cabozantinib for Recurrent CNS Tumors in Children
NCT02885324Phase 2Terminated
- Sponsor
- Indiana University
- Start
- May 2017
- Primary completion
- Aug 2020
- Modality
- Small Molecules
- Countries
- 1
01
Overview
A Phase 2 trial of cabozantinib in central nervous system tumor, glioblastoma multiforme (GBM), anaplastic astrocytoma (AA), high-grade glioma (HGG), sponsored by Indiana University. Started May 2017; status: terminated.
02
Drugs
cabozantinib
03
Conditions
central nervous system tumorglioblastoma multiforme (GBM)anaplastic astrocytoma (AA)high-grade glioma (HGG)
Beyond the preview
Go deeper on NCT02885324.
Study design, results and competitive context are available in the Gosset platform where reported.
Competitive context
Available in the Gosset platform where reported.
Bring the full picture into focus.
See how Gosset can support your research on NCT02885324.